Home
  >  
Section 58
  >  
Chapter 57,376

Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal

Rogers, J.E.; Silva, N.N.; Eng, C.

Journal of Gastrointestinal Oncology 6(5): E82-E85

2015

ISSN/ISBN: 2078-6891
PMID: 26487956
DOI: 10.3978/j.issn.2078-6891.2015.035
Accession: 057375503
Download citation:  
Text
  |  
BibTeX
  |  
RIS
Metastatic squamous cell carcinoma (SCC) of the anal canal is rare with limited data regarding treatment. Epidermal growth factor receptor (EGFR) expression has been observed in SCC of the anal canal and Kristen rat sarcoma vial oncogene (KRAS) mutations are rare. EGFR monoclonal antibodies, cetuximab and panitumumab, represent a potential option in this patient population. We report a metastatic SCC of the anal canal patient treated with cetuximab in combination with cisplatin plus 5-Fluorouracil (5-FU) that had a dramatic response.

PDF emailed within 0-6 h: $19.90




Related References

Hober, C.; Jamme, P.; Desmedt, E.; Greliak, A.; Mortier, L. 2021: Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab Therapeutic Advances in Medical Oncology 13: 17588359211015493
Jaiyesimi, I.A.; Pazdur, R. 1993: Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal American Journal of Clinical Oncology 16(6): 536-540
Olivatto, L.O.; Meton, F.; Bezerra, M.; Cardoso, A.; Araujo, C.M.; Castro, L.; Moura, R.; Pereira, B.V.; Ferreira, C.G. 2016: Phase I study of cetuximab (CET) in combination with 5-fluorouracil (5-FU), cisplatin (CP), and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC) Journal of Clinical Oncology 26(15_Suppl): 4609-4609
Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Duck, L.; Bessa, E.; Mueser, M.; Amellal, N. 2003: Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck EJC Suppls 1(5): S34
Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Humblet, Y.; Lopez-Pousa, A.; Hitt, R.; Vega Villegas, M.E.; Duck, L.; Rosine, D.; Amellal, N.; Schueler, A.; Harstrick, A. 2006: Phase I/Ii study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24(18): 2866-2872
Olivatto, L.O.; Vieira, F.M.; Pereira, B.V.; Victorino, A.P.; Bezerra, M.; Araujo, C.M.; Erlich, F.; Faroni, L.; Castro, L.; Lusis, E.C.; Marins, A.; Ferreira, C.G. 2013: Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma Cancer 119(16): 2973-2980
Moreno, V.; García-Carbonero, R.; Maurel, J.; Feliu, J. 2014: Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma Cancer 120(3): 454-456
Lorenzen, S.; Schuster, T.; Porschen, R.; Al-Batran, S.-E.; Hofheinz, R.; Thuss-Patience, P.; Moehler, M.; Grabowski, P.; Arnold, D.; Greten, T.; Müller, L.; Röthling, N.; Peschel, C.; Langer, R.; Lordick, F. 2009: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase Ii study of the Arbeitsgemeinschaft Internistische Onkologie Annals of Oncology: Official Journal of the European Society for Medical Oncology 20(10): 1667-1673
Shahjehan, F.; Kamatham, S.; Ritter, A.; Kasi, P.M. 2019: Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer Clinical Case Reports 7(9): 1729-1734
Guo, Y.; Luo, Y.; Zhang, Q.; Huang, X.; Li, Z.; Shen, L.; Feng, J.; Sun, Y.; Yang, K.; Ge, M-H.; Zhu, X.; Wang, L.; Liu, Y.; He, X.; Bai, C.; Xue, K.; Zeng, Y.; Cao, Y.; Chen, W.; Lin, T. 2018: First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 9: Ix176
Vermorken, J.B.; Mesia, R.; Vega-Villegas, M.E.; Remenar, E.; Hitt, R.; Kawecki, A.; Rottey, S.; Zabolotnyy, D.; Erfan, J.; Amellal, N. 2016: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME) Journal of Clinical Oncology 24(18_Suppl): 5537-5537
Rogers, J.E.; Eng, C. 2014: Cetuximab in refractory squamous cell carcinoma of the anal canal Journal of Gastrointestinal Cancer 45(Suppl 1): 198-200
Lerner, J.; Michel, M.; Dasanu, C.A. 2020: Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners 26(4): 1025-1028
Machiels, J.-P.; Kaminsky, M.-C.; Keller, U.; Brümmendorf, T.H.; Goddemeier, T.; Forssmann, U.; Delord, J.-P. 2013: Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck Investigational new Drugs 31(5): 1207-1216
Ryohei Kawabata; Hiroshi Imamura; Tomono Kishimoto; Shinji Kitamura; Yoshimi Hachino; Yukako Yasui; Misako Fujino; Chika Fujii; Hiroshi Furukawa 2011: Second-line combination chemotherapy with docetaxel and nedaplatin for metastatic or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus cisplatin Esophagus 8(3): 179-185